Avanos Medical CFO Departs; New Directors Appointed

Ticker: AVNS · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1606498

Avanos Medical, INC. 8-K Filing Summary
FieldDetail
CompanyAvanos Medical, INC. (AVNS)
Form Type8-K
Filed DateOct 23, 2025
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $1,535,417, $1,425,665
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors

Related Tickers: AVNS

TL;DR

CFO out, interim CFO in, two new board members join Avanos.

AI Summary

On October 21, 2025, Avanos Medical, Inc. announced the departure of its Chief Financial Officer, Robert J. Blount, effective October 25, 2025. The company also appointed Todd W. Miller as interim CFO. Additionally, the company elected two new directors, David L. Johnson and Michael J. Prevoznik, to its Board of Directors.

Why It Matters

The departure of a CFO can signal strategic shifts or financial concerns, while new board members may bring fresh perspectives or influence future company direction.

Risk Assessment

Risk Level: medium — CFO departures and board changes can indicate internal instability or strategic realignments that may impact future performance.

Key Players & Entities

FAQ

Who is the departing Chief Financial Officer of Avanos Medical, Inc.?

Robert J. Blount is the departing Chief Financial Officer.

When is Robert J. Blount's departure effective?

Robert J. Blount's departure is effective October 25, 2025.

Who has been appointed as the interim Chief Financial Officer?

Todd W. Miller has been appointed as the interim Chief Financial Officer.

How many new directors were elected to the Board?

Two new directors, David L. Johnson and Michael J. Prevoznik, were elected.

What is the company's principal executive office address?

The company's principal executive office is located at 5405 Windward Parkway, Suite 100 South, Alpharetta, Georgia 30004.

Filing Stats: 793 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-10-23 07:01:49

Key Financial Figures

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVANOS MEDICAL, INC. Date: October 23, 2025 By: /s/ John J. Hurley John J. Hurley Controller

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing